Shelhigh, FDA settle dispute over GMP (good manufacturing practices) faults
This article was originally published in Clinica
Executive Summary
Shelhigh, a manufacturer of tissue-based cardiothoracic implants, has told Clinica that it is looking to resume operations at its New Jersey facility "in a few weeks" after having reached a truce with the FDA over the company's alleged violation of good manufacturing practices (GMPs).